
Life Sciences
Boston Biotech Rezera Says Its Pill Boosts Semaglutide's Anti-Inflammatory Effect
Rezera reported positive Phase 2 results on October 7, 2026 for ruvonoflast combined with semaglutide in 82 adults with obesity.
Boston Business Watch reported on University of Colorado Anschutz on October 7, 2026.
October 7, 2026
Rezera reported positive Phase 2 results on October 7, 2026 for ruvonoflast combined with semaglutide in 82 adults with obesity.

Life Sciences
Rezera reported positive Phase 2 results on October 7, 2026 for ruvonoflast combined with semaglutide in 82 adults with obesity.